trending Market Intelligence /marketintelligence/en/news-insights/trending/aVSkFcxV1zKrwpqh4KTBiw2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Lilly's Verzenio fails phase 3 trial in non-small cell lung cancer

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Lilly's Verzenio fails phase 3 trial in non-small cell lung cancer

Eli Lilly and Co. said the phase 3 trial of Verzenio as a monotherapy in KRAS-mutated, advanced non-small lung cancer failed to meet its main goal.

Results from the JUNIPER study showed that Verzenio was not superior to Roche Holding AG and Astellas Pharma Inc.'s Tarceva, or erlotinib, and did not meet the end goal for overall survival.

However, an analysis of the secondary study endpoints of both progression-free survival and overall response rate showed evidence of monotherapy activity in the Verzenio arm of the study.

The U.S. Food and Drug Administration approved Verzenio, or abemaciclib, in September to treat advanced or metastatic breast cancer that has progressed following endocrine therapy.